NDAORALTABLET
Approved
May 2011
Lifecycle
Peak
Competitive Pressure
0/100
Clinical Trials
20
Data completeness
6/8 — Strong
TRADJENTA (linagliptin) by Boehringer Ingelheim is dipeptidyl peptidase 4 inhibitors [moa]. Approved for dipeptidyl peptidase 4 inhibitor [epc]. First approved in 2011.
Drug data last refreshed Yesterday · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
TRADJENTA (linagliptin) is an oral small-molecule dipeptidyl peptidase-4 (DPP-4) inhibitor approved by the FDA in May 2011 for the treatment of type 2 diabetes mellitus. It works by inhibiting DPP-4, an enzyme that inactivates incretin hormones, thereby increasing insulin secretion and decreasing glucagon levels in a glucose-dependent manner. TRADJENTA is positioned as a monotherapy or adjunctive therapy option in the DPP-4 inhibitor class, which represents a well-established but mature segment of the antidiabetic market.
$1.3BPart D
11.6 years to LOEMechanism of Action
Dipeptidyl Peptidase 4 Inhibitors
Pharmacologic Class:
Dipeptidyl Peptidase 4 Inhibitor
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (20)
The Bioequivalence Study of Linagliptin 5 mg Film-coated Tablet in Healthy Thai Volunteers
Started Apr 2024
48 enrolled
Healthy Volunteer
Real-world Study Comparing the Adherence and Effectiveness of Linagliptin vs. Acarbose
Started Mar 2020
85 enrolled
Diabetes Mellitus, Type 2
This Study in Healthy People Tests Whether Taking a Low Strength of Empagliflozin, Linagliptin, and Metformin Together in 1 Pill is the Same as Taking Them in Separate Pills
Started Aug 2018
30 enrolled
Healthy
Diabetes Study of Linagliptin and Empagliflozin in Children and Adolescents (DINAMO)TM
Started Mar 2018
175 enrolled
Diabetes Mellitus, Type 2
Real World Glycemic Effectiveness of Linagliptin
Started Nov 2017
11,001 enrolled
Diabetes Mellitus, Type 2
Worked on TRADJENTA at Boehringer Ingelheim? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.